Mood disorder and epilepsy: A neurobiologic perspective of their relationship

Dialogues in Clinical Neuroscience

Volumn 10, Issue 1, 2008, Pages 39-45

  Kanner, Andres M ^a,b,c  

^a RUSH MEDICAL COLLEGE   (United States)

^b Laboratory of Electroencephalography and Video EEG Telemetry

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Genetically epilepsy prone rat; Hippocampal atrophy; Major depressive disorder; Norepinephrine; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 AMINOBUTYRIC ACID; 4 FLURO N 2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YLLETHYL N (2 PYRIDYL)CYCLOHEXANECARHOXAMIDE] F 18; 4,2 (METHOXYPHENYL) 1 ALPHA[2 (N 2 PYRIDINYL) 4 FLUOROBENZA MIDO]ETHYLPIPERAZINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; GLUTAMIC ACID; INDORENATE; LAMOTRIGINE; MONOAMINE OXIDASE INHIBITOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE C 11; NEUROTRANSMITTER; NORADRENALIN; OXCARBAZEPINE; PROBENECID; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRACER; UNCLASSIFIED DRUG; VALPROIC ACID; VERAPAMIL;

CHEMICAL ANALYSIS; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; EPILEPSY; HUMAN; INSTRUMENTAL CONDITIONING; MOOD DISORDER; NEUROBIOLOGY; NEUROPATHOLOGY; NEUROPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; TEMPORAL LOBE EPILEPSY;

BRAIN; BRAIN CHEMISTRY; COMORBIDITY; DEPRESSIVE DISORDER; EPILEPSY; EPILEPSY, TEMPORAL LOBE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOOD DISORDERS; NEUROTRANSMITTER AGENTS; RISK FACTORS; SEROTONIN;

EID: 42149136808     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Kanner AM, Balabanov A. Depression in epilepsy: How closely related are these two disorders? Neurology. 2002;58(suppl 5):S27-S39.
2. Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48:2336-2344.
3. Mazarati A, Shin D, Auvin S, Caplan R, Sankar R. Kindling epileptogenesis in immature rats leads to persistent depressive behavior. Epilepsy Behav 2007;10:377-383.
4. Schildkraut JJ. The catecholamine hypothesis of effective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509-522.
5. Jobe PC, Weber RH. Affective disorder and epilepsy comorbidity in the genetically epilepsy prone-rat (GEPR). In: Gilliam FG, Kanner AM, Sheline YI, eds. Depression and Brain Dysfunction. London, UK: Taylor & Francis; 2006:121-158.
6. Clough RW, Peterson BR, Steenbergen JL et al. Neurite extension of developing noradrenergic neurons is impaired in genetically epilepsy-prone rats (GEPR-3s): An in vitro study on locus coeruleus. Epilepsy Res. 1998;29:135-146.
7. Ryu JR, Jobe PC, Milbrandt JC, et al. Morphological deficits in noradrenergic neurons in GEPR-9s stem from abnormalities in both the locus coeruleus and its target tissues. Exp Neurol. 1999;156:84-91.
8. Yan QS, Jobe PC, Dailey JW. Thalamic deficiency in norepinephrine release detected via intracerebral microdialysis: a synaptic determinant of seizure predisposition in the genetically epilepsy-prone rat. Epilepsy Res. 1993;14:229-236.
9. Dailey JW, Mishra PK, Ko KH, Penny JE, Jobe PC. Serotonergic abnormalities in the central nervous system of seizure-naive genetically epilepsy-prone rats. Life Sci. 1992;50:319-326.
10. Yan QS, Jobe PC, Dailey JW. Further evidence of anticonvulsant role for 5-hydroxytryptamine in genetically epilepsy prone rats. Br J Pharmacol. 1995;115:1314-1318.
11. Yan QS, Jobe PC, Dailey JW. Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsyprone rats. Eur J Pharmacol. 1993;252:105-112.
12. Lehmann A. Audiogenic seizures data in mice supporting new theories of biogenic amines mechanisms in the central nervous system. Life Sci. 1967;6:1423.
13. Pole P, Schneeberger J, Haefely, W. Effects of several centrally active drugs on the sleep wakefulness cycle of cats. Neuropharmacology. 1979;18:259.
14. Piette Y, Delaunois AL, De Shaepdryver AF, Heymans C. Imipramine and electroshock threshold. Arch Int Pharmacodyn Ther. 1963;144:293.
15. Yanagita T, Wakasa Y, Kiyohara H. Drug-dependance potential of viloxazine hydrochloride tested in rhesus monkeys. Pharmacol Biochem Behav. 1980;12:155.
16. Beck SG, Choi KC. 5-Hydroxytryptamine hyperpolartizes CA3 hippocampal pyramidal cells through an increase in potassium conductance. Neurosci Lett. 1991;133:93-96.
17. Yan QS, Mishra PK, Burger RL, Bettendorf AF, Jobe PC, Dailey JW. Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats. J Pharmacol Exp Ther. 1992;261:652-659.
18. Southern E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol. 1998;358:19-24.
19. Whitton PS, Fowler LJ. The effect of valproic acid on 5-hydroxytryptamine and 5- hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo. Eur J Pharmacol. 1991;200:167-169.
20. Lopez-Meraz ML, Gonzalez-Trujano ME, Neri-Bazan L, Hong E, Rocha LL. 5-HT1A receptor agonists modify seizures in three experimental models in rats. Neuropharmacology. 2005;49:367-375.
21. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10- hydroxicarbamazepine. Neurosci Lett. 2005;16:390:48-53.
22. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Quantitative in-vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther. 2005;314:725-731.
23. Naritokku DK, Terry WJ, aHelfert RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res. 1995;22:53.
24. Browning, Ra, Clark KB, Naritoku, DK, Smith DC and Jensen RA. Loss of anticonvulsant effect of vagus nerve stimulation in the pentylenetetrazol seizure model following treatment with 6-hydroxydopamine or 5,7-dihydroxy- tryptamine. Soc Neurosci. 1997;23:2424.
25. Langer SZ, Galzin AM. Studies on the serotonin transporter in platelets. Experientia. 1988;44:127-130.
26. Nemeroff CB, Knight DL, Krishnan RR et al. Marked reduction in the number of platelet-tritiated Imipramine binding sites in geriatric depression. Arch Gen Psychiatry. 1988;45:919-923.
27. Malison RT, Price LH, Berman R et al. Reduced brain serotonin transporter availability in major depression as measured by[123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry. 1998;44:1090-1098.
28. Ogilvie AD, Harmar AJ. Association between the serotonin transporter gene and affective disorder: the evidence so far. Mol Med. 1997;3:90-93.
29. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, Gunn RN, Grasby PM, Cowen PJ. Brain serotonin1A receptor binding measured by positron emission tomography with.[11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57:174-180.
30. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46:1375-1387.
31. Cheetham SC, Crompton MR, Katona CL, Horton RW. Brain 5-HT1 binding sites in depressed suicides. Psychopharmacology. 1990;102:544-548.
32. Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci. 1998;18:7394-7401.
33. Toczek MT, Carson RE, Lang L, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology. 2003;60:749-756.
34. Savic I, Lindstrom P, Gulyas B, Halldin C, Andree B, Farde L. Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology. 2004;62:1343-1351.
35. Merlet I, Ostrowsky K, Costes N, Ryvlin P, Isnard J, Faillenot I, Lavenne F, Dufournel D, Le Bars D, Mauguiere F. 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an.[18F]MPPF-PET study. Brain. 2004;127:900-913.
36. Meschaks A, Lindstrom P, Halldin C, Farde L, Savic I. Regional reductions in serotonin 1A receptor binding in Juvenile Myoclonic Epilepsy. Arch Neurol. 2005;62:946-960.
37. Hasler G, Bonwetsch R, Giovacchini G, et al. 5-HT(1A) receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry. 2008. In press.
38. Theodore WH, Giovacchini G, Bonwetsch R, et al. The effect of antiepileptic drugs on 5-HT-receptor binding measured by positron emission tomography. Epilepsia. 2006;47:499-503.
39. Gilliam FG, Maton BM, Martin RC, et al. Hippocampal 1H-MRSI correlates with severity of depression symptoms in temporal lobe epilepsy. Neurology. 2007;68:364-368.
40. Forsgren L, Nystrom L. An incident case referent study of epileptic seizures in adults. Epilepsy Res. 1999;6:66-81.
41. Hesdorffer DC, Hauser WA, Annegers JF, et al. Major depression is a risk factor for seizures in older adults. Ann Neurol. 2000;47:246-249.
42. Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O. Depression and suicidal attempt as risk factor for incidental unprovoked seizures. Ann Neurol. 2006;59:35-41.
43. Jones JE, Watson R, Sheth R, et al. Psychiatric comorbidity in children with new onset epilepsy. Dev Med Child Neurol. 2007;49:493-497.
44. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
45. McAfee AT, Chilcott KE, Johannes CB, Hornbuckle K, Hauser WA, Walker AM. The incidence of first unprovoked seizure in pediatric patients with and without psychiatric diagnsoses. Epilepsia. 2007;48:1075-1082.
46. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. Epilepsy Res. 2007;75:192-196.
47. Anhoury S, Brown RJ, Krishnamoorthy ES and Trimble MR. Psychiatric outcome after temporal lobectomy: a predictive study. Epilepsia. 2000;41:1608-1615.
48. Kanner AM, Byrne R, Smith MC, Balabanov A, Frey M. Does a lifetime history of depression predict a worse postsurgical seizure outcome following a temporal lobectomy? Ann Neurol. 2006;60:(S:10):19 (Abstract).
49. Sheline YI. Brain structural changes associated with depression. In: Gilliam FG, Kanner AM, Sheline YI, eds. Depression and Brain Dysfunction. London, UK: Taylor & Francis; 2006:85-104.